Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.75
-3.3%
$2.29
$1.70
▼
$14.85
$17.46M1.38110,909 shs26,184 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.47
-2.7%
$1.12
$0.46
▼
$2.55
$15.25M0.881.23 million shs108,501 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.18
+5.6%
$3.12
$0.72
▼
$20.32
$20.97M1.261.77 million shs214,731 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.42
+6.0%
$1.45
$1.06
▼
$4.94
$5.18M1.9539,987 shs172,622 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-4.74%-10.84%-29.30%-30.12%-84.73%
Celularity, Inc. stock logo
CELU
Celularity
-15.41%-35.67%-58.35%-37.01%-72.24%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+5.10%-7.21%-25.90%-56.72%+18.39%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-2.19%+2.29%-5.63%-10.67%-70.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.75
-3.3%
$2.29
$1.70
▼
$14.85
$17.46M1.38110,909 shs26,184 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.47
-2.7%
$1.12
$0.46
▼
$2.55
$15.25M0.881.23 million shs108,501 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.18
+5.6%
$3.12
$0.72
▼
$20.32
$20.97M1.261.77 million shs214,731 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.42
+6.0%
$1.45
$1.06
▼
$4.94
$5.18M1.9539,987 shs172,622 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-4.74%-10.84%-29.30%-30.12%-84.73%
Celularity, Inc. stock logo
CELU
Celularity
-15.41%-35.67%-58.35%-37.01%-72.24%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+5.10%-7.21%-25.90%-56.72%+18.39%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-2.19%+2.29%-5.63%-10.67%-70.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
2.50
Moderate Buy$20.331,061.90% Upside
Celularity, Inc. stock logo
CELU
Celularity
1.00
SellN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.50
Moderate BuyN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PULM, ATOS, EDSA, and CELU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Reiterated RatingSell (E+)
9/21/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Reiterated RatingSell (E+)
9/8/2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Reiterated RatingSell (E+)
8/27/2026
Celularity, Inc. stock logo
CELU
Celularity
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/A$2.18 per shareN/A
Celularity, Inc. stock logo
CELU
Celularity
$18.67M0.82N/AN/A($1.32) per share-0.36
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81M0.66N/AN/A$2.45 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$34.77M-$2.62N/AN/AN/AN/A-117.07%-96.08%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$1.69N/AN/AN/A-246.65%N/A-48.20%N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.69N/AN/AN/AN/A-560.22%-105.74%12/11/2026 (Estimated)
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$5.16M-$1.10N/AN/AN/AN/A-163.02%-110.34%N/A

Latest PULM, ATOS, EDSA, and CELU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/11/2026N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.58N/AN/AN/AN/AN/A
11/17/2026Q3 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$2.00-$0.34+$1.66-$0.34$1.53 millionN/A
11/10/2026Q3 2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$0.8567-$0.56+$0.2967-$0.56N/AN/A
10/20/2026Q2 2026
Celularity, Inc. stock logo
CELU
Celularity
N/A$0.02N/A$0.02N/A$5.43 million
9/29/2026Q1 2026
Celularity, Inc. stock logo
CELU
Celularity
N/A$0.02N/A$0.02N/A$3.85 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A
5.35
5.35
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.11
0.10
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
2.76
2.76
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
4.70
4.70

Institutional Ownership

CompanyInstitutional Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%

Insider Ownership

CompanyInsider Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
9.80%
Celularity, Inc. stock logo
CELU
Celularity
52.90%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
149.98 million9.00 millionOptionable
Celularity, Inc. stock logo
CELU
Celularity
11532.45 million15.28 millionOptionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
179.64 million7.29 millionNot Optionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
23.65 million3.63 millionNot Optionable

Recent News About These Companies

Pulmatrix Inc : PULM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$1.75 -0.06 (-3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$1.75 0.00 (0.00%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Celularity stock logo

Celularity NASDAQ:CELU

$0.47 -0.01 (-2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$0.46 0.00 (-1.06%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$2.17 +0.12 (+5.58%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 -0.11 (-5.24%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$1.42 +0.08 (+5.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 -0.05 (-3.80%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.